Welcome to Helix Talk, a podcast presented by the Rosalind Franklin University College of Pharmacy.

We're hoping that our real-life clinical pearls and discussions will help you stay up to date and improve your pharmacy knowledge.

This podcast contains general information for educational purposes only.

This is not professional advice and should not be used in lieu of obtaining advice from a

qualified health care provider.

And now, on to the show.

Welcome to Helix Talk Episode 29.

I'm your co-host, Dr. Cain.

And I'm Dr. Patel.

And today we're actually taking a recommendation, a couple of recommendations that we received online.

We're very passionate about receiving topic recommendations from our listeners.

And we actually received a number of requests that we talk about therapeutic drug monitoring.

So we've actually selected two drugs each.

And Dr. Schumann is not with us today, but he'll be with us for the second segment of this.

And we're going to be talking about therapeutic drug monitoring in terms of how to get a level for certain medications, what to do with that level, how to adjust it, and kind of clinical pearls and pitfalls associated with those medications.

And when you think about therapeutic monitoring, few drugs come to mind right away.

Things like Vanitoin, lithium, warfarin is another one.

And a lot of controversies arise there.

There are some guidelines out there by the governing bodies.

However, there are some institutional- specific guidelines too. So I understand

how confusing it can get. Yeah, and one of the hallmarks, the reason why these medications have

therapeutic drug monitoring chapters associated with them is that they have a narrow therapeutic

...